Abstract
Objective:
To compare etanercept (anti-tumor necrosis factor-α) with intraarticular (IA) corticosteroid injections to treat rheumatoid arthritis (RA).
Methods:
Patients with RA who had persistent monoarthritis received etanercept or IA corticosteroid injections. Efficacy was compared at Weeks 4 and 24.
Results:
Thirty-four patients were included (8 dropped out). Mean age was 58.8 years. No difference between groups was found at Weeks 4 or 24, but both groups showed significant improvement at Weeks 4 and 24 compared to baseline.
Conclusion:
Etanercept and IA steroid injections resulted in significant improvement at Week 4 that persisted to Week 24. There was no significant difference in outcome between the groups.
Publication types
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adrenal Cortex Hormones / administration & dosage
-
Adrenal Cortex Hormones / adverse effects
-
Adrenal Cortex Hormones / therapeutic use*
-
Antirheumatic Agents / administration & dosage
-
Antirheumatic Agents / adverse effects
-
Antirheumatic Agents / therapeutic use*
-
Arthritis, Rheumatoid / blood
-
Arthritis, Rheumatoid / diagnostic imaging
-
Arthritis, Rheumatoid / drug therapy*
-
Blood Sedimentation
-
Dose-Response Relationship, Drug
-
Double-Blind Method
-
Etanercept
-
Female
-
Humans
-
Immunoglobulin G / administration & dosage
-
Immunoglobulin G / adverse effects
-
Immunoglobulin G / therapeutic use*
-
Injections, Intra-Articular
-
Longitudinal Studies
-
Male
-
Middle Aged
-
Pilot Projects
-
Receptors, Tumor Necrosis Factor / administration & dosage
-
Receptors, Tumor Necrosis Factor / therapeutic use*
-
Treatment Outcome
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
-
Ultrasonography
Substances
-
Adrenal Cortex Hormones
-
Antirheumatic Agents
-
Immunoglobulin G
-
Receptors, Tumor Necrosis Factor
-
Tumor Necrosis Factor-alpha
-
Etanercept